Balingit, J. C., Abe, M., Suzuki, R., Xayavong, D., Ngwe Tun, M. M., Takamatsu, Y., Sonoda, K., & Morita, K. (2025).
Cross-genotype immunogenicity and antibody-dependent enhancement of KD-382 dengue vaccine in flavivirus-naïve adults. Npj Vaccines, 10(1), 148.
https://doi.org/10.1038/s41541-025-01204-y
Abstract
This exploratory study evaluated the neutralization breadth and potential antibody-dependent enhancement (ADE) risk following a single-dose of the KD-382 live-attenuated tetravalent dengue vaccine over 12 months in flavivirus-naïve healthy adults. Using single-round infectious particles representing 17 dengue virus genotypes, KD-382-induced antibodies demonstrated durable cross-genotype neutralizing activity, with minimal in vitro ADE risk. These findings highlight KD-382’s potential for broad protection and underscore the importance of long-term monitoring in dengue-naïve populations.
